Effect of targeting inflammation with salsalate: The TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins

JAMA Cardiology

Volumn 1, Issue 4, 2016, Pages 413-423

  Hauser, Thomas H ^a,b   Salastekar, Ninad ^a,b,c   Schaefer, Ernst J ^d   Desai, Tanvi ^b,c   Goldfine, Harvey L ^e   Fowler, Kristen M ^c   Weber, Griffin M ^a,b   Welty, Francine ^a,b   Clouse, Melvin ^a,b   Shoelson, Steven E ^b,c   Goldfine, Allison B ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d TUFTS UNIVERSITY   (United States)

^e Metro West Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; BILIRUBIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SALSALATE; TRIACYLGLYCEROL; URIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALBUMINURIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN ISCHEMIA; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; CORONARY ARTERY PLAQUE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM ARRHYTHMIA; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE COUNT; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEPHROLITHIASIS; NEUTROPHIL COUNT; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; TINNITUS; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; ATHEROSCLEROTIC PLAQUE; COMPLICATION; MIDDLE AGED;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PLAQUE, ATHEROSCLEROTIC; SALICYLATES;

EID: 85016166509     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.0605     Document Type: Article

References (36)

1. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: From pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-2138.
2. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7): 1793-1801.
3. Rana JS, Boekholdt SM, Ridker PM, et al. Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: The EPIC-Norfolk Prospective Population Study. J Intern Med. 2007;262(6):678-689.
4. Kaptoge S, Di Angelantonio E, Lowe G, et al; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet. 2010;375(9709): 132-140.
5. Jack DB. One hundred years of aspirin. Lancet. 1997;350(9075):437-439.
6. Goldfine AB, Fonseca V, Jablonski KA, et al; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: A randomized trial. Ann Intern Med. 2013;159(1):1-12.
7. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract. 2012;18(6):826-833.
8. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56 (4):714-723.
9. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2013;50(4):537-543.
10. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol. 2005;16(2):459-466.
11. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, ViamonteMJr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827-832.
12. Burgstahler C, Reimann A, Beck T, et al. Influence of a lipid-lowering therapy on calcified and noncalcified coronary plaques monitored by multislice detector computed tomography: Results of the New Age II Pilot Study. Invest Radiol. 2007;42 (3):189-195.
13. Gibson CM, Sandor T, Stone PH, Pasternak RC, Rosner B, Sacks FM. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. Am J Cardiol. 1992; 69(16):1286-1290.
14. Hsieh FY, Bloch DA, Larsen MD. A simple method of sample size calculation for linear and logistic regression. Stat Med. 1998;17(14):1623-1634.
15. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-612.
16. Xu J, Murphy SL, Kochanek KD, Bastian BA. Deaths: Final data for 2013. Natl Vital Stat Rep. 2016;64(2):1-119.
17. Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(2):199-207.e15. doi:10.1016/j.ahj .2013.03.018.
18. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605.
19. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337(5):356].NEngl J Med. 1997;336(14):973-979.
20. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med. 2003;139(8):670-682.
21. Denoble AE, Huffman KM, Stabler TV, et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A. 2011;108(5):2088-2093.
22. Halperin F, Beckman JA, Patti ME, et al. The role of total and high-molecular-weight complex of adiponectin in vascular function in offspring whose parents both had type 2 diabetes. Diabetologia. 2005;48(10):2147-2154.
23. Sandfort V, Lima JA, Bluemke DA. Noninvasive imaging of atherosclerotic plaque progression: Status of coronary computed tomography angiography. Circ Cardiovasc Imaging. 2015;8(7): E003316. doi:10.1161/CIRCIMAGING.115.003316.
24. Tardif JC, L'allier PL, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010;3(3):298-307.
25. Hoffmann H, Frieler K, Schlattmann P, Hamm B, Dewey M. Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. Eur Radiol. 2010;20(12): 2824-2833.
26. Inoue K, Motoyama S, Sarai M, et al. Serial coronary CT angiography-verified changes in plaque characteristics as an end point: Evaluation of effect of statin intervention. JACC Cardiovasc Imaging. 2010;3(7):691-698.
27. ShimojimaM, Kawashiri MA, Nitta Y, et al. Rapid changes in plaque composition and morphology after intensive lipid lowering therapy: Study with serial coronary CT angiography. Am J Cardiovasc Dis. 2012;2(2):84-88.
28. Zeb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression: A serial coronary CT angiography study. Atherosclerosis. 2013;231(2):198-204.
29. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65(13):1273-1282.
30. Atkinson MH, Menard HA, Kalish GH. Assessment of salsalate, a nonacetylated salicylate, in the treatment of patients with arthritis. Clin Ther. 1995;17(5):827-837.
31. Morris HG, Sherman NA, McQuain C, Goldlust MB, Chang SF, Harrison LI. Effects of salsalate (nonacetylated salicylate) and aspirin on serum prostaglandins in humans. Ther Drug Monit. 1985;7 (4):435-438.
32. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
33. Demeure F, Hanin FX, Bol A, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: Implications for vulnerable coronary plaque imaging. J Nucl Med. 2014;55(10):1629-1635.
34. Joshi NV, Toor I, Shah AS, et al. Systemic atherosclerotic inflammation following acute myocardial infarction:myocardial infarction begets myocardial infarction. J Am Heart Assoc. 2015;4(9): E001956. doi:10.1161/JAHA.115.001956.
35. Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: Comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3(4):388-397.
36. Lo J, LuMT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: A randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2(2):e52-e63. doi:10.1016 /S2352-3018(14)00032-0.